Andrew K. Balo Sells 5,000 Shares of DexCom Inc. (DXCM) Stock
DexCom Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of DexCom stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $82.55, for a total transaction of $412,750.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Andrew K. Balo also recently made the following trade(s):
- On Wednesday, September 21st, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $92.87, for a total transaction of $464,350.00.
Shares of DexCom Inc. (NASDAQ:DXCM) opened at 82.93 on Friday. The stock’s market cap is $6.96 billion. The firm’s 50-day moving average is $90.88 and its 200 day moving average is $77.91. DexCom Inc. has a 52-week low of $47.92 and a 52-week high of $96.38.
DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.12. The company had revenue of $137.30 million for the quarter, compared to analysts’ expectations of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The company’s quarterly revenue was up 47.3% compared to the same quarter last year. During the same period last year, the business earned ($0.05) EPS. Analysts forecast that DexCom Inc. will post ($0.57) earnings per share for the current fiscal year.
A number of equities research analysts recently weighed in on DXCM shares. Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “strong sell” rating in a report on Tuesday. Desjardins upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Friday, September 16th. Benchmark Co. decreased their price objective on shares of DexCom from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, August 3rd. Jefferies Group reiterated a “positive” rating and set a $98.00 price objective on shares of DexCom in a report on Friday, July 22nd. Finally, BTIG Research lowered shares of DexCom from a “buy” rating to a “neutral” rating and set a $92.00 price objective for the company. in a report on Wednesday, September 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $95.08.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Riverhead Capital Management LLC bought a new position in shares of DexCom during the first quarter valued at $3,951,000. AXA raised its position in shares of DexCom by 2.5% in the first quarter. AXA now owns 524,721 shares of the medical device company’s stock valued at $35,634,000 after buying an additional 12,791 shares during the period. State Street Corp raised its position in shares of DexCom by 7.2% in the first quarter. State Street Corp now owns 1,055,774 shares of the medical device company’s stock valued at $71,699,000 after buying an additional 71,009 shares during the period. Cupps Capital Management LLC raised its position in shares of DexCom by 20.9% in the first quarter. Cupps Capital Management LLC now owns 43,464 shares of the medical device company’s stock valued at $2,951,000 after buying an additional 7,518 shares during the period. Finally, Menta Capital LLC bought a new position in shares of DexCom during the first quarter valued at $679,000. 99.37% of the stock is owned by institutional investors.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.